Navigation Links
Sertraline Can Prevent Recurrent Depressive Episodes In Diabetics

A study published in the Archives of General Psychiatry has now revealed that the risk of recurrent depression in diabetics may be effectively prevented by the antidepressant medication, Sertraline. //In addition to reducing the frequency of depressive episodes, the drug has also been found to increase the time interval between episodes of depression in diabetics.

It is believed that one in 4 diabetics end up with a diagnosis of clinical depression, leading to a substantial reduction in the quality of life and functional ability. In addition, it can increase the risk of high blood sugar level, diabetic complications and even death.

Conventional treatment with psychotherapy and anti-depressant medication has been found to be effective. However, this is only useful in short term. Furthermore, previous studies have shown that 1 in 7 diabetic patients developed resistance to the commonly used anti-depressant medication owing to incidence of recurrent depression, placing them at an increased risk for abnormally high blood sugar levels.

The researchers included 152 diabetics, all of whom had recovered from their first bout of depression following treatment with sertraline. The study participants were followed for a minimum of one year or till such time their depression recurred. During the same time, they were randomly assigned into two groups; with the experimental group receiving sertraline while the control group received a placebo instead.

Following detection of depression associated symptoms; the patients underwent a psychiatric interview. The patients’ hemoglobin levels, more specifically Hb A1c, an indicator of the blood glucose control level over the past two or three months was measured every two months.

At the end of the study, patients taking sertraline had a reduced risk of developing recurrent depression when compared to their counterparts. At the end of one year, 65.8% of the patients taking sert raline remained in remission from their depression, compared with 47.9% of those in the control group. The time interval between recurrent episodes of depression was found to be 226 days and 57 days in the sertraline and the control group respectively.

‘Using data available at the one-year point, the number needed to be treated was six patients, i.e., it would be necessary to treat six patients to spare one patient from depression recurrence,’ the authors write. All participants’ Hb A1c levels had decreased when they recovered from depression and remained lower as long as they remained depression-free, with no difference between the two study groups. Depression is increasingly understood as a recurrent and debilitating disease, especially for those with diabetes, the authors write. Physicians suspect that the more time an individual spends depressed, the greater the risk for diabetic complications and death. ‘Our study establishes a clear benefit of sertraline for prevention of depression recurrence in patients with diabetes,’ remarked the study authors.

‘Sertraline lengthened the depression-free interval of maintenance and did not interfere with glycemic improvement achieved during the recovery phase. Treatment with sertraline is relatively simple, safe and widely available, and although it is not curative, it offers patients with diabetes a potentially viable method for ameliorating the suffering, incapacity and burden associated with recurrent depression,’ concluded the researchers.

'"/>




Related medicine news :

1. Lose stomach for Life....Preventive removal of stomach saves the risk of cancer
2. Prevention is better than cure
3. Prevention of cataracts
4. Medications to Prevent Relapse to Cocaine Use
5. Estrogen Does Not Prevent Recurrent Strokes
6. Over-The-Counter Drugs May Prevent Alzheimers
7. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
8. Alcoholism Drug Fails To Prevent Drinking Relapses
9. Preventing mental decline in the aged
10. Preventing white coat hypertension
11. Simple Stroke Prevention is Best
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
Breaking Medicine Technology: